Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity

Anthracyclines play an irreplaceable role in cancer treatment, although their clinical application is limited due to severe side effects such as arrhythmia, cardiomyopathy, and myocardial infarction. The currently available clinical drugs for treating anthracycline-induced cardiotoxicity (AIC) are l...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rongrong Bai, Zhigao Zhao, Xing Han, Mingying Shang, Guangxue Liu, Feng Xu, Shaoqing Cai
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Molecules
Subjects:	anthracyclines anthracycline cardiotoxicity cardiotoxicity ginsenosides oxidative stress cardiovascular diseases
Online Access:	https://www.mdpi.com/1420-3049/30/12/2527
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01)

MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances
by: Hongyun Mao, et al.
Published: (2025-08-01)

Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
by: Lili Zhang, et al.
Published: (2025-04-01)

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review
by: Xiao S, et al.
Published: (2025-07-01)

Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis
by: Ling Yin Fritz Wong, et al.
Published: (2025-07-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study
by: Árpád Kézdi, et al.
Published: (2025-04-01)

Treatment of cardiotoxicity in patients with invasive breast cancer during neoadjuvant chemotherapy
by: Grigorii A. Ignatenko, et al.
Published: (2024-09-01)

Randomized, Placebo‐Controlled, Triple‐Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline‐Based Cancer Therapy
by: Stephanie Itala Rizk, et al.
Published: (2025-05-01)

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis
by: Runyu Liu, et al.
Published: (2025-07-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials
by: Siyu Li, et al.
Published: (2025-07-01)

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Evaluation of left atrial strain changes in patients with breast cancer after anthracycline therapy
by: Mostafa El Mokadem, et al.
Published: (2025-05-01)

Efficacy and harms associated with β-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
by: Jessica T. Li, et al.
Published: (2024-06-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

Utility of global longitudinal strain in early identification of chronic cardiotoxicity in asymptomatic long-term malignant lymphoma survivors with normal left ventricle ejection fraction
by: Eva Rihackova, et al.
Published: (2025-03-01)

Combined Utility of Speckle Tracking Echocardiography and Cardiac Biomarkers for Early Detection of Anthracycline-Induced Cardiotoxicity in Pediatric Oncology Patients
by: Cristiana Stolojanu, et al.
Published: (2024-12-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)

A review of cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity
by: Hadi Zare-Zardini, et al.
Published: (2024-12-01)

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
by: E. V. Grakova, et al.
Published: (2023-01-01)

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity
by: V. D. Levina, et al.
Published: (2022-12-01)

Age‐Related Long‐Term Longitudinal Changes in Left Ventricular Mechanical Function in Breast Cancer Patients Undergoing Anthracycline and Trastuzumab Treatment
by: Begimai Akbalaeva, et al.
Published: (2025-04-01)

Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines
by: Iokfai Cheang, et al.
Published: (2025-06-01)

Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
by: Rizkyastari Onny, et al.
Published: (2025-06-01)

Cardioprotective effect of thiotriazoline in cancer patients
by: A. V. Koltsov, et al.
Published: (2023-02-01)

Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
by: A. A. Avagimyan, et al.
Published: (2021-11-01)

Cardio- and nephroprotective effects of fractions isolated from Lycium barbarum (goji berry) in models of cardio- and nephrotoxicity in rats
by: Nadezhda Hvarchanova, et al.
Published: (2023-03-01)

Exercise training partly ameliorates cardiac dysfunction in mice during doxorubicin treatment of breast cancer
by: Tytti-Maria Uurasmaa, et al.
Published: (2025-01-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
by: V. I. Chernov, et al.
Published: (2016-12-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Dynamics of SERPINA3 in response to anthracycline treatment and cardiovascular dysfunction
by: Hanne M. Boen, et al.
Published: (2025-03-01)